Journal of Crohn's and Colitis
IF
8.66
Papers
2531
Papers 8608
1 page of 861 pages (8,608 results)
Newest
#1Renate A A A Ruigrok (UMCG: University Medical Center Groningen)
#2Valerie Collij (UMCG: University Medical Center Groningen)H-Index: 7
Last. Arnau Vich Vila (UMCG: University Medical Center Groningen)H-Index: 18
view all 12 authors...
BACKGROUND AND AIMS The human gastrointestinal tract harbours distinct microbial communities essential for health. Little is known about small intestinal communities, despite the small intestine playing a fundamental role in nutrient absorption and host-microbe immune homeostasis. We aimed to explore the small intestine microbial composition and metabolic potential, in the context of inflammatory bowel disease (IBD). METHODS Metagenomes derived from faecal samples and extensive phenotypes were c...
Source
Source
#1S Restellini (MUHC: McGill University Health Centre)H-Index: 1
#1Sophie Restellini (University of Geneva)H-Index: 9
Last. Peter L. Lakatos (MUHC: McGill University Health Centre)H-Index: 84
view all 2 authors...
Source
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Jonathan P Segal (Imperial College Healthcare)H-Index: 11
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 6 authors...
BACKGROUND 5-aminosalicylates (5-ASAs) are the mainstay of treatment for ulcerative colitis (UC). The optimum preparation, dose, and route of administration for UC remains unclear. We conducted a network meta-analysis to examine this issue. METHODS We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials from inception to December 2020. We included randomised controlled trials (RCTs) comparing oral, topical, or combined oral and topical 5-ASAs, with eac...
2 CitationsSource
#1Walter Reinisch (Medical University of Vienna)H-Index: 100
#2William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
Last. Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
view all 18 authors...
BACKGROUND AND AIMS Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM1, induced remission in patients with moderate-to-severe ulcerative colitis (UC) in TURANDOT. We assessed long-term safety, tolerability and efficacy of ontamalimab in TURANDOT II. METHODS TURANDOT II was a phase 2, multicentre, open-label (OL) study in patients with moderate-to-severe UC who completed TURANDOT on placebo or ontamalimab. Patients were randomized to 75mg or 225mg ontamalimab every 4 weeks for 72 we...
Source
Source
Source
Source
Source
Source
12345678910
Top fields of study
Inflammatory bowel disease
Crohn's disease
Ulcerative colitis
Medicine
Gastroenterology